Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.
Article
CAS
Google Scholar
McCullough A, Previs SF, Dasarathy J, Lee K, Osme A, Kim C, et al. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2019;317(5):E852–62.
Article
CAS
Google Scholar
Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis. 2018;17(1):1–8.
Article
Google Scholar
Schrutka L, Distelmaier K, Hohensinner P, Sulzgruber P, Lang IM, Maurer G, et al. Impaired high-density lipoprotein anti-oxidative function is associated with outcome in patients with chronic heart failure. J Am Heart Assoc. 2016. https://doi.org/10.1161/JAHA.116.004169.
Article
PubMed
PubMed Central
Google Scholar
Schrutka L, Distelmaier K, Hohensinner P, Sulzgruber P, Lang IM, Maurer G, et al. Impaired high-density lipoprotein anti-oxidative function is associated with outcome in patients with chronic heart failure. J Am Heart Assoc. 2016;5(12):e004169.
Article
Google Scholar
Amor AJ, Pinyol M, Solà E, Catalan M, Cofán M, Herreras Z, et al. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: a focus on atherogenic dyslipidemia. J Clin Lipidol. 2017;11(2):551-61.e7.
Article
Google Scholar
Orozco Morales JA, Medina Urrutia AX, Torres Tamayo M, Jorge Galarza E, Reyes Barrera J, Díes Suarez P, et al. Effects of fatty liver on the size and composition of high-density lipoprotein cholesterol subpopulations in adolescents with type 2 diabetes mellitus. Pediatr Diabetes. 2020;21(7):1140–9.
Article
CAS
Google Scholar
Rao PK, Merath K, Drigalenko E, Jadhav AYL, Komorowski RA, Goldblatt MI, et al. Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. Clin Proteom. 2018;15:10.
Article
Google Scholar
Morze J, Koch M, Aroner SA, Budoff M, McClelland RL, Mukamal KJ, et al. Associations of HDL subspecies defined by ApoC3 with non-alcoholic fatty liver disease: the multi-ethnic study of atherosclerosis. J Clin Med. 2020. https://doi.org/10.3390/jcm9113522.
Article
PubMed
PubMed Central
Google Scholar
Annema W, Willemsen HM, de Boer JF, Dikkers A, van der Giet M, Nieuwland W, et al. HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels. J Clin Lipidol. 2016;10(6):1318–28.
Article
Google Scholar
Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol. 2011;58(20):2068–75.
Article
CAS
Google Scholar
Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes. 2011;60(10):2617–23.
Article
CAS
Google Scholar
Zhang J, Zhang Y, Liu H, Bai H, Wang Y, Jiang C, et al. Antioxidant properties of high-density lipoproteins are impaired in women with polycystic ovary syndrome. Fertil Steril. 2015;103(5):1346–54.
Article
CAS
Google Scholar
Fadaei R, Poustchi H, Meshkani R, Moradi N, Golmohammadi T, Merat S. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep. 2018;8(1):11691.
Article
Google Scholar
van den Berg EH, Gruppen EG, Ebtehaj S, Bakker SJL, Tietge UJF, Dullaart RPF. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease. Atherosclerosis. 2018;277:21–7.
Article
Google Scholar
Wang B, Yang RN, Zhu YR, Xing JC, Lou XW, He YJ, et al. Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease. Mol Med Rep. 2017;15(1):387–95.
Article
CAS
Google Scholar
Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radical Biol Med. 2020;152:116–41.
Article
CAS
Google Scholar
Ito F, Ito T, Suzuki C, Yahata T, Ikeda K, Hamaoka K. The application of a modified d-ROMs test for measurement of oxidative stress and oxidized high-density lipoprotein. Int J Mol Sci. 2017;18(2):454.
Article
Google Scholar
Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, et al. Oxidative stress and pro-inflammatory status in patients with non-alcoholic fatty liver disease. Antioxidants. 2020. https://doi.org/10.3390/antiox9080759.
Article
PubMed
PubMed Central
Google Scholar
Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem. 2010;285(24):18473–84.
Article
CAS
Google Scholar
Schill RL, Knaack DA, Powers HR, Chen Y, Yang M, Schill DJ, et al. Modification of HDL by reactive aldehydes alters select cardioprotective functions of HDL in macrophages. FEBS J. 2020;287(4):695–707.
Article
CAS
Google Scholar
Sehitogulları A, Aslan M, Sayır F, Kahraman A, Demir H. Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep. 2014;19(5):199–205.
Article
Google Scholar
Arya A, Azarmehr N, Mansourian M, Doustimotlagh AH. Inactivation of the superoxide dismutase by malondialdehyde in the nonalcoholic fatty liver disease: a combined molecular docking approach to clinical studies. Arch Physiol Biochem. 2019. https://doi.org/10.1080/13813455.2019.1659827.
Article
PubMed
Google Scholar
Świderska M, Maciejczyk M, Zalewska A, Pogorzelska J, Flisiak R, Chabowski A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD) Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radic Res. 2019;53(8):841–50.
Article
Google Scholar
Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an urban iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (polyiran—liver)—study protocol. Arch Iran Med. 2015;18(8):515–23.
PubMed
Google Scholar
Breton CV, Yin F, Wang X, Avol E, Gilliland FD, Araujo JA. HDL anti-oxidant function associates with LDL level in young adults. Atherosclerosis. 2014;232(1):165–70.
Article
CAS
Google Scholar
Lee SB, Park G-M, Lee J-Y, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study. J Hepatol. 2018;68(5):1018–24.
Article
Google Scholar
Gaál K, Tarr T, Lőrincz H, Borbás V, Seres I, Harangi M, et al. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. Lipids Health Dis. 2016;15(1):1–8.
Article
Google Scholar
Ito F, Ito T. High-density lipoprotein (Hdl) triglyceride and oxidized HDL: new lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease. Antioxidants. 2020;9(5):362.
Article
CAS
Google Scholar
Carnuta MG, Stancu CS, Toma L, Sanda GM, Niculescu LS, Deleanu M, et al. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Sci Rep. 2017;7(1):1–13.
Article
CAS
Google Scholar
Milaciu MV, Vesa ȘC, Bocșan IC, Ciumărnean L, Sâmpelean D, Negrean V, et al. Paraoxonase-1 serum concentration and PON1 gene polymorphisms: relationship with non-alcoholic fatty liver disease. J Clin Med. 2019;8(12):2200.
Article
CAS
Google Scholar
Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011;12(2):80–5.
Article
CAS
Google Scholar
van den Berg EH, Gruppen EG, James RW, Bakker SJL, Dullaart RPF. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. J Lipid Res. 2019;60(1):168–75.
Article
Google Scholar
Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34(1):57–62.
CAS
PubMed
Google Scholar
Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106(3):261–8.
Article
CAS
Google Scholar
Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 1,00,667 patients. Circulation. 2020;142(7):621–42.
Article
CAS
Google Scholar